The FDA granted Priority Review to J&J’s subcutaneous RYBREVANT FASPRO (amivantamab plus hyaluronidase-lpuj) for recurrent or metastatic head and neck squamous cell carcinoma after platinum chemotherapy and PD-1/PD-L1 treatment, anchored by the OrigAMI-4 Phase 1b/2 results. The submission targets EGFR and MET signaling and would add a new administration route for patients with limited options. In parallel, the FDA awarded Breakthrough Therapy Designation to Lilly’s KRAS G12C inhibitor olomorasib for advanced pancreatic cancer in the LOXO-RAS-20001 Phase 1/2 study. The designation is based on early clinical signals in KRAS G12C–mutant advanced solid tumors, where no KRAS G12C therapy is currently approved for pancreatic cancer. Together, the two decisions underscore regulator momentum toward earlier, mechanism-defined oncology options—one expanding a recently disclosed response profile in head and neck cancer, the other accelerating development for KRAS-driven pancreatic disease using an FDA-approved biomarker test.